The text only version may be available in large print, Braille or audio CD. For further information call emc accessibility on 0800 198 5000. The product code(s) for this leaflet is: PLGB 11972/0010.
Descovy 200 mg/10 mg film-coated tablets
Descovy 200 mg/10 mg film-coated tablets
1. What Descovy is and what it is used for
2. What you need to know before you take Descovy
3. How to take Descovy
4. Possible side effects
5. How to store Descovy
6. Contents of the pack and other information
Descovy contains two active substances:
Descovy blocks the action of the reverse transcriptase enzyme, which is essential for the virus to multiply. Descovy, therefore, reduces the amount of HIV in your body.
Descovy in combination with other medicines is for the treatment of human immunodeficiency virus 1 (HIV-1) infection in adults and adolescents 12 years of age and older, who weigh at least 35 kg.
You must remain under the care of your doctor while taking Descovy.
This medicine is not a cure for HIV infection. While taking Descovy you may still develop infections or other illnesses associated with HIV infection.
Once you start taking Descovy, look out for:
There is a possibility that you may experience kidney problems when taking Descovy over a long period of time (see Warnings and precautions).
Do not give this medicine to children aged 11 years or under, or weighing less than 35 kg. The use of Descovy in children aged 11 years or under has not yet been studied.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Descovy may interact with other medicines. As a result, the amounts of Descovy or other medicines in your blood may change. This may stop your medicines from working properly, or may make any side effects worse. In some cases, your doctor may need to adjust your dose or check your blood levels.
You should not take Descovy with medicines containing:
Talk to your doctor if you are taking:
If you have taken Descovy during your pregnancy, your doctor may request regular blood tests and other diagnostic tests to monitor the development of your child. In children whose mothers took NRTIs during pregnancy, the benefit from the protection against HIV outweighed the risk of side effects.
Do not breast-feed during treatment with Descovy. This is because one of the active substances in this medicine passes into breast milk.
Breast-feeding is not recommended in women living with HIV because HIV infection can be passed on to the baby in breast milk.
If you are breast-feeding, or thinking about breast-feeding, you should discuss it with your doctor as soon as possible.
Descovy can cause dizziness. If you feel dizzy when taking Descovy, do not drive and do not use any tools or machines.
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free’.
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
Adults: one tablet each day, with or without food
Adolescents 12 years of age and older, who weigh at least 35 kg: one tablet each day with or without food
It is recommended not to chew or crush the tablet due to the bitter taste.
If you have difficulty swallowing the tablet whole, you can split it in half. Take both halves of the tablet one after the other to get the full dose. Do not store the split tablet.
Always take the dose recommended by your doctor. This is to make sure that your medicine is fully effective, and to reduce the risk of developing resistance to the treatment. Do not change the dose unless your doctor tells you to.
If you are on dialysis, take your daily dose of Descovy following completion of dialysis.
If you take more than the recommended dose of Descovy you may be at higher risk of side effects of this medicine (see section 4, Possible side effects).
Contact your doctor or nearest emergency department immediately for advice. Keep the tablet bottle with you so that you can show what you have taken.
It is important not to miss a dose of Descovy.
If you do miss a dose:
If you vomit less than 1 hour after taking Descovy, take another tablet.
Do not stop taking Descovy without talking to your doctor. Stopping Descovy can seriously affect how well future treatment works. If Descovy is stopped for any reason, speak to your doctor before you restart taking Descovy tablets.
When your supply of Descovy starts to run low, get more from your doctor or pharmacist. This is very important because the amount of virus may start to increase if the medicine is stopped for even a few days. The disease may then become harder to treat.
If you have both HIV infection and hepatitis B, it is very important not to stop taking Descovy without talking to your doctor first. You may require blood tests for several months after stopping treatment. In some patients with advanced liver disease or cirrhosis, stopping treatment may lead to worsening of hepatitis, which may be life-threatening.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Very common side effects
(may affect more than 1 in 10 people)
Common side effects
(may affect up to 1 in 10 people)
Uncommon side effects
(may affect up to 1 in 100 people)
The frequency of the following side effects is not known (frequency cannot be estimated from the available data).
During HIV therapy there may be an increase in weight and in levels of blood lipids and glucose. This is partly linked to restored health and life style, and in the case of blood lipids sometimes to the HIV medicines themselves. Your doctor will test for these changes.
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and bottle after “EXP”. The expiry date refers to the last day of that month.
Store in the original package in order to protect from moisture. Keep the bottle tightly closed.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
The active substances are emtricitabine and tenofovir alafenamide. Each Descovy film-coated tablet contains 200 mg of emtricitabine and tenofovir alafenamide fumarate equivalent to 10 mg of tenofovir alafenamide.
The other ingredients are
Microcrystalline cellulose, croscarmellose sodium, magnesium stearate.
Polyvinyl alcohol, titanium dioxide, macrogol 3350, talc, iron oxide black (E172).
Descovy film-coated tablets are grey, rectangular-shaped tablets, debossed on one side with “GSI” and the number “210” on the other side of the tablet.
Descovy comes in bottles of 30 tablets (with a silica gel desiccant that must be kept in the bottle to help protect your tablets). The silica gel desiccant is contained in a separate sachet or canister and should not be swallowed.
The following pack sizes are available: outer cartons containing 1 bottle of 30 film-coated tablets and outer cartons containing 60 (2 bottles of 30) and 90 (3 bottles of 30) film-coated tablets. Not all pack sizes may be marketed.
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
This leaflet was last revised in 06/2023.
DVY - 53041